[1]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132-134137.[doi:10.3969/j.issn.1006-1959.2019.18.044]
　ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Medical Information,2019,32(18):132-134137.[doi:10.3969/j.issn.1006-1959.2019.18.044]
点击复制

安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年18期
页码:
132-134137
栏目:
药物与临床
出版日期:
2019-09-15

文章信息/Info

Title:
Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites
文章编号:
1006-1959（2019）18-0132-04
作者:
张秀芳1; 陈 萍2
1.锦州医科大学湖北医药学院研究生培养基地，湖北 十堰 442000；2.十堰市人民医院/湖北医药学院附属人民医院，湖北 十堰 442000
Author(s):
ZHANG Xiu-fang1; CHEN Ping2
1.Graduate Training Base of Hubei Medical College of Jinzhou Medical University,Shiyan 442000, Hubei,China;2.Shiyan People’s Hospital/Affiliated People’s Hospital of Hubei Medical College,Shiyan 442000, Hubei,China
关键词:
安罗替尼; 顺铂; 卵巢癌; 恶性腹腔积液; CA125
Keywords:
Key words：Erlotinib; Cisplatin; Ovarian cancer; Malignant ascites; CA125
分类号:
R737.31
DOI:
10.3969/j.issn.1006-1959.2019.18.044
文献标志码:
A
摘要:
目的 研究安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效。方法 选取2017年9月~2018年9月十堰市人民医院收治的48例晚期卵巢癌并发腹腔积液患者为研究对象，随机分为实验组和对照组，各24例。对照组静脉给予顺铂治疗，实验组在对照组基础上加用安罗替尼治疗，比较两组患者的临床疗效、不良反应发生情况及生活质量改善情况，并检测腹腔积液CA125水平。结果 实验组患者的近期疗效总有效率高于对照组（87.50% vs 58.33%），差异有统计学意义（P＜0.05）。实验组治疗后1、2、3周腹腔积液CA125水平低于对照组，差异有统计学意义（P＜0.05）。两组不良反应发生率比较，差异无统计学意义（P＞0.05）。观察组患者的生活质量改善率高于对照组（83.33% vs 54.17%），差异有统计学有意义（P＜0.05）。结论 安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效显著，不仅可明显改善患者生活质量、降低其不良反应发生率，而且可降低CA125水平，患者耐受程度较好，值得临床参考。
Abstract:
Abstract：Objective To study the efficacy of ilotinib combined with cisplatin in the treatment of advanced ovarian cancer with malignant ascites. Methods 48 patients with advanced ovarian cancer complicated with ascites were enrolled in the Shiyan People’s Hospital from September 2017 to September 2018. They were randomly divided into experimental group and control group, 24 cases each. The control group was treated with cisplatin intravenously. The experimental group was treated with ilotinib on the basis of the control group. The clinical efficacy, adverse reaction and quality of life were compared between the two groups, and the level of CA125 in the peritoneal effusion was measured. Results The total effective rate of the short-term efficacy of the experimental group was higher than that of the control group (87.50% vs 58.33%),the difference was statistically significant (P<0.05). The level of CA125 in the ascites of the experimental group was lower than that of the control group at 1, 2, and 3 weeks after treatment,the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The improvement rate of quality of life in the observation group was higher than that in the control group (83.33% vs 54.17%),the difference was statistically significant (P<0.05). Conclusion The efficacy of erlotinib combined with cisplatin in the treatment of advanced ovarian cancer malignant ascites is significant, not only can significantly improve the quality of life of patients, reduce the incidence of adverse reactions, but also reduce the level of CA125, patients with better tolerance, worthy of clinical reference.

参考文献/References:

[1]Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.[2]Piche A.Malignant peritoneal effusion acting as a tumor environment in ovarian cancer progression:Impact and significance[J].World J Clin Oncol,2018,9(8):167-171.[3]Kipps E,Tan DS,Kaye SB.Meeting the challenge of ascites in ovarian cancer:new avenues for therapy and research[J].Nat Rev Cancer,2013,13(4):273-282.[4]Huang L,Huang Z,Bai Z,et al.Development and strategies of VEGFR-2/KDR inhibitors[J].Future Med Chem,2012,4(14):1839-1852.[5]Han B,Li K,Wang Q,et al.Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer:The ALTER 0303 Phase 3 Randomized Clinical Trial[J].JAMA Oncol,2018,4(11):1569-1575.[6]王睿晴,张艳华.抗肿瘤分子靶向药物安罗替尼的临床研究进展[J].中国新药杂志,2018,27(23):2770-2774.[7]岳凯.安罗替尼胶囊联合顺铂治疗非小细胞肺癌恶性胸腔积液的价值研究[J].中国合理用药探索,2018,15(11):84-86,93.[8]蒋徐维,郝余庆,朱锋.甲磺酸阿帕替尼片治疗胃肠恶性肿瘤合并腹水的临床疗效研究[J].中国肿瘤临床与康复,2018,25(2):168-171.[9]Penet MF,Krishnamachary B,Wildes FB.Ascites Volumes and the Ovarian Cancer Microenvironment[J].Front Oncol,2018(8):595-602.[10]Chen CY,Chang HP,Ng KK,et al.Long-term disease-free survival in three ovarian cancer patients with a single relapse[J].Eur J Gynaecol Oncol,2012,33(3):321-323.[11]王彦洁,李小平,杨欣.卵巢上皮性肿瘤腹水的治疗现状及进展[J].中国妇产科临床杂志,2014,15(2):189-192.[12]Lin B,Song X,Yang D,et al.Anlotinib inhibits angiogenesisvia suppressing the activation of VEGFR2,PDGFRβ and FGFR1[J].Gene,2018,15(654):77-86.[13]Ruan X,Shi X,Dong Q,et al.Antitumor effects of anlotinib in thyroid cancer[J].Endocr Relat Cancer,2019,26(1):153-164.[14]Sun Y,Niu W,Du F,et al.Safety,pharmacokinetics,and antitumor properties of anlotinib,an oral multi-target tyrosine kinase inhibitor,in patients with advanced refractory solid tumors[J].J Hematol Oncol,2016,9(1):105-113.[15]Reck M,Barlesi F,Crinò L,et al.Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab:a consensus report from a panel of experts[J].Ann Oncol,2012,23(5):1111-1120.

相似文献/References:

[1]刘贤丰,李子俊.恩度联合培美曲塞与顺铂治疗晚期肺腺癌的临床效果观察[J].医学信息,2019,32(03):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
　LIU Xian-feng,LI Zi-jun.Clinical Observation of Endo Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma[J].Medical Information,2019,32(18):148.[doi:10.3969/j.issn.1006-1959.2019.03.048]
[2]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2022,35(18):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[3]刘 贝,郑 慧,周 旺,等.3D-STI联合心脏综合指数评价肺癌患者GP化疗方案的隐匿性心肌毒性[J].医学信息,2019,32(08):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
　LIU Bei,ZHENG Hui,ZHOU Wang,et al.Evaluation of Occult Myocardial Toxicity in GP Chemotherapy Regimen of Lung Cancer Patients by 3D-STI Combined with Cardiac Comprehensive Index[J].Medical Information,2019,32(18):100.[doi:10.3969/j.issn.1006-1959.2019.08.029]
[4]李菡旖.顺铂同步放化疗方案治疗中晚期宫颈癌的疗效[J].医学信息,2019,32(24):103.[doi:10.3969/j.issn.1006-1959.2019.24.034]
　LI Han-yi.Efficacy of Cisplatin Concurrent Chemoradiotherapy for Advanced Cervical Cancer[J].Medical Information,2019,32(18):103.[doi:10.3969/j.issn.1006-1959.2019.24.034]
[5]任勇军,闵旭立,徐 浩,等.洛铂联合表柔比星化疗栓塞治疗原发性肝细胞癌的疗效[J].医学信息,2019,32(24):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
　REN Yong-jun,MIN Xu-li,XU Hao,et al.Efficacy of Loplatin Combined with Epirubicin Chemotherapy and Embolization for Primary Hepatocellular Carcinoma[J].Medical Information,2019,32(18):43.[doi:10.3969/j.issn.1006-1959.2019.24.014]
[6]李 博.紫杉醇加顺铂治疗晚期老年非小细胞癌的疗效[J].医学信息,2020,33(10):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
　LI Bo.Paclitaxel Plus Cisplatin in the Treatment of Advanced Elderly Non-small Cell Carcinoma[J].Medical Information,2020,33(18):153.[doi:10.3969/j.issn.1006-1959.2020.10.045]
[7]厉 锋,鲍 乐,丁轶人,等.安罗替尼治疗晚期肝癌患者的效果[J].医学信息,2020,33(18):138.[doi:10.3969/j.issn.1006-1959.2020.18.045]
　LI Feng,BAO Le,DING Yi-ren,et al.Anlotinib in the Treatment of Patients with Advanced Liver Cancer[J].Medical Information,2020,33(18):138.[doi:10.3969/j.issn.1006-1959.2020.18.045]
[8]王鹏飞,李崇慧.加味沙参麦冬汤联合安罗替尼治疗晚期非小细胞肺癌的临床观察[J].医学信息,2021,34(02):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
　WANG Peng-fei,LI Chong-hui.Clinical Observation of Modified Shashen Maidong Decoction Combined with Anlotinib in the Treatment of Advanced Non-small Cell Lung Cancer[J].Medical Information,2021,34(18):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6在安罗替尼治疗的非小细胞肺癌中的表达及临床意义[J].医学信息,2023,36(01):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.The Expression and Clinical Significance of Serum KL-6 in Non-small Cell Lung Cancer Treated with Anlotinib[J].Medical Information,2023,36(18):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]
[10]苏 凝,樊利萍,秦丽丽,等.恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效[J].医学信息,2021,34(11):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
　SU Ning,FAN Li-ping,QIN Li-li,et al.Efficacy of Endu Combined with Cisplatin Intrapleural Perfusion in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Medical Information,2021,34(18):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]

更新日期/Last Update: 2019-09-15